Bi-specific T-cell engager

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 9, 2023
Workforce, Amgen, Epithelial cell adhesion molecule, Doctor of Philosophy, Regeneron Pharmaceuticals, CD3, Therapeutic index, Exelixis, Cancer, Lead, EST, Bristol Myers Squibb, Research, Inflammation, PST, Genentech, Trial of the century, Acquisition, Patent, Patient, AbbVie, Investment, EGFR, SAN, CD71, Webcast, Interferon, ADC, BMS, Cytokine, Spacecraft, Therapy, Bi-specific T-cell engager, Tumor microenvironment, Safety, TCB, Pharmaceutical industry, Astellas Pharma, Moderna, IND

“As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody® therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.

Key Points: 
  • “As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody® therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
  • CX-904 is partnered with Amgen and is being evaluated by CytomX in an ongoing Phase 1 study in patients with advanced solid tumors.
  • CytomX and Astellas are collaborating on additional conditionally activated TCB programs, and CytomX is eligible to receive future preclinical, clinical, and commercial milestones.
  • ET (2 p.m. PT) to discuss the financial results and provide a business update.

NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Thursday, February 16, 2023
ACT, TAA, Countersurveillance, NEXI, Immunotherapy, Lymphocyte function-associated antigen 1, AIM, CD4, Maintenance, Immunological memory, Patient, Bi-specific T-cell engager, Neoplasm, Hackensack University Medical Center, Discovery, Associate, Biting, Innovation, Transplant, Observation, CD8, Hackensack Meridian Health, Vaccine

AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory.

Key Points: 
  • AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory.
  • The abstract describes the ability of multi-TAA AIM ACT T cells to work synergistically with BiTE therapy, revealing several important advantages over endogenous TAA nonspecific CD8 T cells + BiTE.
  • The results show that BiTE potency, as measured by a reduction in tumor burden in vivo, is markedly increased in the presence of AIM T cells.
  • This observation strongly suggests that AIM ACT T cells provide immunosurveillance following the withdrawal of the BiTE, a distinct advantage over bulk CD8+ T cells, which should contribute to the maintenance of remission.

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Retrieved on: 
Wednesday, January 4, 2023
Cancer, Standard of care, Clinical trial, Partnership, Death, Lung, Bi-specific T-cell engager, Fulvestrant, CLDN9, Female, Breast cancer, Breast, Toxicity, Metastasis, OATH, PFS, Growth, Patient, Endometrial cancer, Uterus, PR, FDA, IND, SMILE, Progesterone, Taxane, Survival, CLDN6, Context, Birth control, Pharmaceutical industry

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today provided 2022 year-end updates and corporate guidance for 2023.

Key Points: 
  • "I am proud of the substantial progress the Context team made in 2022.
  • "In 2023, we will continue to advance ONA-XR across the endometrial (OATH) and breast (SMILE and ELONA) cancer clinical trials.
  • During Q4 2022, Context presented preclinical data introducing CTIM-76 as a differentiated, potent, and selective CLDN6-directed immunotherapy.
  • IND-enabling studies are scheduled for 2023 with an IND filing to support human clinical trials expected in Q1 2024.

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Retrieved on: 
Thursday, December 22, 2022
MEM, OTCQB, Bi-specific T-cell engager, Research, COVID-19, Biomarker, Virus, USD, CAR, CRS, Patient, Michigan State University, Degenerative disease, Syndrome, Innovation, Cytokine, Cannabinoid, Therapy, Cytokine release syndrome, Immune system, GBLX, Bispecific monoclonal antibody, Vaccine, Pharmaceutical industry

Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.

Key Points: 
  • Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.
  • "Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation.
  • Gb Sciences recently published a white paper on their novel development program titled "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics"; download it here .
  • A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences' proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers.

Simnova and Orna Therapeutics Collaborate to Advance Orna's Next Generation Circular RNA Technology in China

Retrieved on: 
Thursday, January 5, 2023
LNP, Anti-CD19 immunotoxin, Protein, International Metalworking Companies, RNA, Bi-specific T-cell engager, Infection, Ornäs, Orna, CAR, Patient, Therapy, Immune system, Cell, Pharmaceutical industry, Vaccine

SHANGHAI, China and CAMBRIDGE, Mass., January 5, 2023  /PRNewswire/ -- Shanghai Xianbo Biotech Co., Ltd., also known as Simnova outside of China, an affiliate of Simcere Investment Group and a clinical-stage biotechnology company developing proprietary off-the-shelf CAR-NK and BiTE-armed CAR-T cell therapies, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, today announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology.

Key Points: 
  • Under the terms of the agreement, Simnova will gain access in greater China to certain programs built on Orna's breakthrough isCAR technology, including Orna's lead anti-CD19 in situ CAR (isCAR) program, ORN-101.
  • In addition, Orna will gain access to investigator-initiated clinical trials in China to accelerate the validation of select programs in patients.
  • "This strategic collaboration broadens Orna's capability to develop circular RNA therapeutics in China through Simnova's development capabilities," said Dr. Zhouxiao Cao, Simnova's Chief Executive Officer.
  • "This marks another important step in our overall business strategy where we look to thoughtfully engage partners to deliver on the promise of circular RNA therapies."

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, December 7, 2022
Breast cancer, Neoplasm, Therapy, Cancer, Clinical trial, United, Amgen, SAN, CD3, Bristol Myers Squibb, EGFR, Cytokine, Safety, ADC, Regeneron Pharmaceuticals, CD71, TNBC, Epithelial cell adhesion molecule, CD166, Risk, AbbVie, Research, COVID-19, Patient, Bi-specific T-cell engager, Pharmaceutical industry

The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).

Key Points: 
  • The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).
  • “We thank our investigators and the patients and families who contributed to our comprehensive evaluation of praluzatamab ravtansine in breast cancer.
  • Praluzatamab ravtansine (CX-2009) is an investigational conditionally activated ADC directed toward CD166 that has demonstrated single agent clinical activity in a Phase 2 study for patients with advanced HR+/HER2-non-amplified breast cancer.
  • Following the Phase 2 results, CytomX decided not to further progress praluzatamab ravtansine alone and is seeking a partner to further develop the molecule.

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities

Retrieved on: 
Tuesday, November 15, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Kinetics, Probability, Biotechnology, ADS, Mouse, Antigen, AbbVie, Bi-specific T-cell engager, Engineering, Therapy, Canadian Aviation Regulations, Multimedia, AstraZeneca, Doctor of Philosophy, Bristol Myers Squibb, CET, NGS, Novartis, Antibody, Fine chemical, Vaccine, Pfizer

Ablexis, LLC (Ablexis), a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (ADS), a leader in the discovery of superior antibody-based therapeutics, which together are leading providers of solutions for the discovery of superior antibody-based therapeutics, announced an expansion of platforms and capabilities in antibody drug discovery and engineering.

Key Points: 
  • Ablexis, LLC (Ablexis), a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (ADS), a leader in the discovery of superior antibody-based therapeutics, which together are leading providers of solutions for the discovery of superior antibody-based therapeutics, announced an expansion of platforms and capabilities in antibody drug discovery and engineering.
  • Ablexis and AlivaMab Discovery Services continue to invest in new technologies that maximize value and flexibility for our partners," said Larry Green, PhD, Chief Executive Officer of Ablexis and AlivaMab Discovery Services.
  • Discovery of Diverse Antibody Panels Using AlivaMab Mouse: The Foundation for Successful Antibody Therapeutics November 16 at 12:15 pm CET.
  • AlivaMab Discovery Services (ADS) sets its partners antibody discovery programs on the fastest and most de-risked path through discovery and development.

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
Bristol Myers Squibb, IND, CD71, Nivolumab, Therapeutic index, Research, Risk, Legacy, Therapy, TCB, Cancer research, Program, ADC, Bi-specific T-cell engager, CD166, Ipilimumab, Tumor microenvironment, Annual general meeting, Amgen, CD3, Cancer, Neoplasm, Patient, Interferon, Camptothecin, COVID-19, Nasdaq, Webcast, Cytokine, United, Clinical trial, Breast cancer, Growth, AbbVie, EGFR, SAN, GLOBE, Head, Epithelial cell adhesion molecule, Investment, ESMO, Workforce, Antibody-drug conjugate, Safety, World, SITC, Triple-negative breast cancer, Pharmaceutical industry, Fine chemical, Vaccine, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update.

Key Points: 
  • - Continued progress with Phase 2 collaborator programs CX-2029 (AbbVie, Phase 2)
    and BMS-986249 (Bristol Myers Squibb, Phase 2) -
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update.
  • CytomXs progress in the third quarter highlights the potential of our pipeline as well as the breadth and versatility of the Probody platform.
  • A data update for the sqNSCLC cohort is expected in the fourth quarter of 2022.
  • ET (2:00 p.m. PT) to discuss the financial results and provide a business update.

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

Retrieved on: 
Monday, November 7, 2022
SAN, GLOBE, Bristol Myers Squibb, CD71, CD166, Risk, Therapeutic index, Annual general meeting, Nasdaq, Immunotherapy, Amgen, Research, Cytokine, Society for Immunotherapy of Cancer, Therapy, PD-L1, CD3, Safety, Cancer, SITC, Toxicity, United, Neoplasm, Clinical trial, Epithelial cell adhesion molecule, ADC, Patient, Breast cancer, Bi-specific T-cell engager, Society, AbbVie, EGFR, COVID-19, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, Massachusetts.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, Massachusetts.
  • Interferon alpha is a clinically validated, powerful antitumor agent, but has historically been limited in its clinical use due to toxicity.
  • At the upcoming SITC Annual Meeting, we will report encouraging preclinical data that support the development of CX-801 based on its single agent activity as well as its enhanced activity when combined with PD-L1 blockade.
  • We plan to explore the clinical potential of CX-801 in tumor types that have traditionally been both responsive and unresponsive to immunotherapy.

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022
Amgen, Cancer, Bristol Myers Squibb, Breast cancer, CD3, CD71, CD166, GLOBE, Nasdaq, Bi-specific T-cell engager, EGFR, Piper Sandler Companies, ADC, Epithelial cell adhesion molecule, Therapy, Cytokine, AbbVie, Patient, Neoplasm, SAN, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.
  • In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
  • CytomX has also established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.